EUVIMEDEUVIMED entdecken
Multizentrische Studie

Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer

Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor iD, Daniel G Schep, Michael Huo, Maggie Stein, Anand Swaminath, Raquibul Hannan, Shankar Siva

BJU International · 2025

DOI: 10.1111/bju.16520 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2025. Verfasst von Muhammad Ali und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Kidney Neoplasms, Radiosurgery, Salvage Therapy, Carcinoma, Renal Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA). Materials and Methods This study was a multi‐institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer‐specific survival (CSS), overall survival (OS), treatment‐related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan–Meier method was used to estimate freedom from local and distant failure, CSS and OS.

Results

Seventeen patients with 18 biopsy‐confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6–68.7) years, a median (IQR) tumour size of 3.5 (1.9–4.1) cm and follow‐up (reverse Kaplan–Meier method) of 3.36 (95% confidence interval [CI] 1.6–4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5–5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression‐free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%–100%), 92.3% (95% CI 78.9%–100%) and 82.1% (95% CI 62.1%–100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40–71) mL/min, and at last follow‐up, it was 48 (33–57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end‐stage renal disease.

Conclusion

The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsRadiosurgerySalvage TherapyCarcinoma, Renal CellNeoplasm Recurrence, LocalHumansMaleAgedFemaleRetrospective StudiesTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

SABRTArenal cell carcinomastereotactic ablative radiotherapythermal ablation

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Radiation Oncology, UT Southwestern Medical Centre, Dallas, TX, USA.
  • Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

ORCID-Profile: David Pryor

Zitieren

APA

Ali, M., Kwon, Y. S., Koo, K., Bruynzeel, A., Pryor, D., Schep, D. G., Huo, M., Stein, M., Swaminath, A., Hannan, R., & Siva, S. (2025). Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. BJU International. https://doi.org/10.1111/bju.16520

Vancouver

Ali M, Kwon YS, Koo K, Bruynzeel A, Pryor D, Schep DG, et al. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. BJU International. 2025. doi:10.1111/bju.16520

BibTeX
@article{Ali2025,
  author = {Ali, Muhammad and Kwon, Young Suk and Koo, Kendrick and Bruynzeel, Anna and Pryor, David and Schep, Daniel G and Huo, Michael and Stein, Maggie and Swaminath, Anand and Hannan, Raquibul and Siva, Shankar},
  title = {Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16520}
}
Kostenlos starten →